Shares of Denbury Resources Inc. (NYSE:DNR) opened at $2.18, and ended 2.69% higher at $2.29. Nearly 9770876 shares were traded by the close, lower than its average daily volume of 14995700 shares.Denbury Resources Inc. (DNR) Analyst Opinion
Denbury Resources Inc. is currently rated as hold by 10 stock analysts, with the company still having around 14.56% shares outstanding that can be sold short legally. The value of their shares went up by 10.1% last month. Over the course of a year, the stock has grown by 33.92%. Financial analysts are becoming more bullish than ever, with the 3 analysts who cover the activities of DNR advising investors to buy. Experts on Wall Street have set a price target of $4.17 for the stock. The decision was arrived after looking at their 82.1% gain from current levels. At the moment, Denbury Resources Inc. (DNR) trading price is around -66.07% below its 52-week high.Denbury Resources Inc. Earnings Surprise
Denbury Resources Inc. (DNR) was successful in overcoming the expected $0.11 as the stock recorded an earnings of $0.13 a piece during their last financial report presentation. Revenue, meanwhile, had a distance of -9.61% from the previous quarter, with the company recording $349.85 million in revenue.Denbury Resources Inc. (NYSE:DNR) Intraday View
The shares of Denbury Resources Inc. (NYSE:DNR) have struggled and recovered 64.75% ever since it recorded its 52 week low. During the course of 5 days, the stock price volatility has remained at 7.09%, increasing the time frame to a month, the volatility recorded was 10.54%. The price of their shares has been successful in staying above its 20 days moving average, staying at a distance of 19.05% and while its 50 moving average is around -5.32%. A look at previous five trading sessionDNR stock had returned 16.24% and sank -42.36% when compared to its 200-day moving average that is $4.13. Denbury Resources Inc. (DNR) will look to keep its 0.88% increase that it witnessed in the past one year.
As the normal trading session ended, the stock of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), fetched in a $0.13 spike to $57.34. The session began with the stock price at $56.74, hitting a high of $57.86 before down again. For the week, analysts seem to be okay with their neutral with the consensus call staying at 2.7. Ionis Pharmaceuticals, Inc. gets 1 buy analyst recommendations while 7 recommend a hold and 0 rated it as a sell. The shares of the company tumbled -4.13% from its high $59.81, with their overall market value now roughly $7.81 billion.Ionis Pharmaceuticals, Inc. (IONS) Consensus Price Target
The mean recommendation of IONS on Reuter’s scale remained unchanged from 2.71 to 2.71 within 30 days. This figure implies that the majority of analysts rate it as a hold. The price target for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is now around $58 a share, implying the stock has what it takes to grow by 1.15%. The recent trading session also indicated the stock needs to add 84.86% more meet analysts’ high consensus price target.Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Intraday Trading
The current trading volume of the company was 928175 shares during the last session. That compares with the recent average volume of 1282060 shares. By the end of the regular trading session, the price volatility over a 1-week span was 3.58 while month stood 4.47%. The stock price of IONS dropped to $56.15 during the day and at a certain time in 12 months it traded as low as $39.07. It has made a 46.76% recovery since its 52-week low point and has returned 6.07% year-to-date.